Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Primary |
Comparison of mean Receptor Activator Of Nuclear Factor-Kappa B Ligand (RANKL) level between peri-implant health and peri-implant mucositis groups |
The RANKL levels in the peri-implant crevicular fluid (PIGF) collected from the patients will be measured via Enzyme-Linked ImmunoSorbent Assay . The difference between the groups will be evaluated. |
this will be done at the beginning of the study, after samples have been collected from all implants in the study. |
|
Primary |
Comparison of mean Osteoprotegerin (OPG) level between peri-implant health and peri-implant mucositis groups |
The OPG levels in the peri-implant crevicular fluid (PIGF) collected from the patients will be measured via Enzyme-Linked ImmunoSorbent Assay . The difference between the groups will be evaluated. |
this will be done at the beginning of the study, after samples have been collected from all implants in the study. |
|
Primary |
Comparison of mean Tumor Necrosis Factor Alpha (TNF-a) level between peri-implant health and peri-implant mucositis groups |
The TNF-a levels in the peri-implant crevicular fluid (PIGF) collected from the patients will be measured via Enzyme-Linked ImmunoSorbent Assay . The difference between the groups will be evaluated. |
this will be done at the beginning of the study, after samples have been collected from all implants in the study. |
|
Primary |
Comparison of mean MicroRNA-223 level between peri-implant health and peri-implant mucositis groups |
The MicroRNA-223 levels in the peri-implant crevicular fluid (PIGF) collected from the patients will be measured via real-time polymerase chain reaction. The difference between the groups will be evaluated. |
this will be done at the beginning of the study, after samples have been collected from all implants in the study. |
|
Primary |
Comparison of mean MicroRNA-27a level between peri-implant health and peri-implant mucositis groups |
The MicroRNA-27a levels in the peri-implant crevicular fluid (PIGF) collected from the patients will be measured via real-time polymerase chain reaction. The difference between the groups will be evaluated. |
this will be done at the beginning of the study, after samples have been collected from all implants in the study. |
|
Primary |
Comparison of alveolar bone loss between adequate Keratinized mucosal thickness (KMT) and inadequate KMT groups |
The bone level measurement will be made by measuring between the bone-implant first contact point and the reference point in the coronal part of the implant body selected for different implant systems in both the mesial and distal directions of the implants. In order to evaluate the marginal bone loss (MBL), the measurements obtained will be compared with the measurements on the radiographs taken after the delivery of the prosthesis. |
It will be done at the start of the study, immediately after the control radiograph is taken. |
|
Primary |
Comparison of alveolar bone loss between between adequate keratinized gingival width (KGW) and inadequate KGW groups |
The bone level measurement will be made by measuring between the bone-implant first contact point and the reference point in the coronal part of the implant body selected for different implant systems in both the mesial and distal directions of the implants. In order to evaluate the marginal bone loss (MBL), the measurements obtained will be compared with the measurements on the radiographs taken after the delivery of the prosthesis. |
It will be done at the start of the study, immediately after the control radiograph is taken. |
|
Primary |
Comparison of mean Receptor Activator Of Nuclear Factor-Kappa B Ligand (RANKL) level between adequate KMT and inadequate KMT groups |
The RANKL levels in the peri-implant crevicular fluid (PIGF) collected from the patients will be measured via Enzyme-Linked ImmunoSorbent Assay . The difference between the groups will be evaluated. |
this will be done at the beginning of the study, after samples have been collected from all implants in the study. |
|
Primary |
Comparison of mean Receptor Activator Of Nuclear Factor-Kappa B Ligand (RANKL) level between adequate KGW and inadequate KGW groups |
The RANKL levels in the peri-implant crevicular fluid (PIGF) collected from the patients will be measured via Enzyme-Linked ImmunoSorbent Assay . The difference between the groups will be evaluated. |
this will be done at the beginning of the study, after samples have been collected from all implants in the study. |
|
Primary |
Comparison of mean Osteoprotegerin (OPG) level between adequate Keratinized mucosal thickness (KMT) and inadequate KMT groups |
The OPG levels in the peri-implant crevicular fluid (PIGF) collected from the patients will be measured via Enzyme-Linked ImmunoSorbent Assay . The difference between the groups will be evaluated. |
this will be done at the beginning of the study, after samples have been collected from all implants in the study. |
|
Primary |
Comparison of mean Osteoprotegerin (OPG) level between between adequate keratinized gingival width (KGW) and inadequate KGW groups |
The OPG levels in the peri-implant crevicular fluid (PIGF) collected from the patients will be measured via Enzyme-Linked ImmunoSorbent Assay . The difference between the groups will be evaluated. |
this will be done at the beginning of the study, after samples have been collected from all implants in the study. |
|
Primary |
Comparison of mean Tumor Necrosis Factor Alpha (TNF-a) level between adequate Keratinized mucosal thickness (KMT) and inadequate KMT groups |
The TNF-a levels in the peri-implant crevicular fluid (PIGF) collected from the patients will be measured via Enzyme-Linked ImmunoSorbent Assay . The difference between the groups will be evaluated. |
this will be done at the beginning of the study, after samples have been collected from all implants in the study. |
|
Primary |
Comparison of mean Tumor Necrosis Factor Alpha (TNF-a) level between between adequate keratinized gingival width (KGW) and inadequate KGW groups |
The TNF-a levels in the peri-implant crevicular fluid (PIGF) collected from the patients will be measured via Enzyme-Linked ImmunoSorbent Assay . The difference between the groups will be evaluated. |
this will be done at the beginning of the study, after samples have been collected from all implants in the study. |
|
Primary |
Comparison of mean MicroRNA-223 level between adequate Keratinized mucosal thickness (KMT) and inadequate KMT groups |
The MicroRNA-223 levels in the peri-implant crevicular fluid (PIGF) collected from the patients will be measured via real-time polymerase chain reaction. The difference between the groups will be evaluated. |
this will be done at the beginning of the study, after samples have been collected from all implants in the study. |
|
Primary |
Comparison of mean MicroRNA-223 level between between adequate keratinized gingival width (KGW) and inadequate KGW groups |
The MicroRNA-223 levels in the peri-implant crevicular fluid (PIGF) collected from the patients will be measured via real-time polymerase chain reaction. The difference between the groups will be evaluated. |
this will be done at the beginning of the study, after samples have been collected from all implants in the study. |
|
Primary |
Comparison of mean MicroRNA-27a level between adequate Keratinized mucosal thickness (KMT) and inadequate KMT groups |
The MicroRNA-27a levels in the peri-implant crevicular fluid (PIGF) collected from the patients will be measured via real-time polymerase chain reaction. The difference between the groups will be evaluated. |
this will be done at the beginning of the study, after samples have been collected from all implants in the study. |
|
Primary |
Comparison of mean MicroRNA-27a level between between adequate keratinized gingival width (KGW) and inadequate KGW groups |
The MicroRNA-27a levels in the peri-implant crevicular fluid (PIGF) collected from the patients will be measured via real-time polymerase chain reaction. The difference between the groups will be evaluated. |
this will be done at the beginning of the study, after samples have been collected from all implants in the study. |
|
Secondary |
Correlation between MBL amounts and TNF-a |
The correlation MBL amounts and TNF-a will be evaluated. |
this will be done at the beginning of the study, after samples have been collected from all implants in the study. |
|
Secondary |
Correlation between MBL amounts and RANKL |
The correlation MBL amounts and RANKL will be evaluated. |
this will be done at the beginning of the study, after samples have been collected from all implants in the study. |
|
Secondary |
Correlation between MBL amounts and OPG |
The correlation MBL amounts and OPG will be evaluated. |
this will be done at the beginning of the study, after samples have been collected from all implants in the study. |
|
Secondary |
Correlation between MBL amounts and MicroRNA-223 |
The correlation MBL amounts and MicroRNA-223 will be evaluated. |
this will be done at the beginning of the study, after samples have been collected from all implants in the study. |
|
Secondary |
Correlation between MBL amounts and MicroRNA-27a |
The correlation MBL amounts and MicroRNA-27a will be evaluated. |
this will be done at the beginning of the study, after samples have been collected from all implants in the study. |
|